Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,307.01 -14.40 (-0.27%) Dow
39,671.04 -201.95 (-0.51%) Nasdaq
16,801.54 -31.08 (-0.18%) Bitcoin USD
69,803.15 -241.05 (-0.34%) CMC Crypto 200
1,502.71 +0.04 (+0.00%)
Cipla Limited (CIPLA.NS)
| Previous close | 1,482.30 |
| Open | 1,482.00 |
| Bid | 1,491.45 x 0 |
| Ask | 1,490.65 x 0 |
| Day's range | 1,462.70 - 1,504.55 |
| 52-week range | 935.00 - 1,519.00 |
| Volume | |
| Avg. volume | 1,992,866 |
| Market cap | 1.203T |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 29.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 13.00 (0.88%) |
| Ex-dividend date | 01 Aug 2024 |
| 1y target est | N/A |
- Zacks
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
- Reuters
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports
Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources. The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said. Cipla did not immediately respond to a Reuters request for comment.
- Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
